Studies With Molecules Within the Same Class, but With Different Designs Yield Different Results. EMPA-REG, CANVAS and DECLARE

doi:10.1016/j.rec.2019.07.009

Revista Española de Cardiología (English Edition)

Volume 72, Issue 12, December 2019, Pages 1095-1096

https://doi.org/10.1016/j.rec.2019.07.009 Get rights and content

Section snippets

CONFLICTS OF INTEREST

A. Gippini has received fees for presentations and advisory boards from AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Janssen, Novartis, NovoNordisk, and Sanofi. A. Prado works in Cardiovascular Renal and Metabolism (CVRM) Medical Department of AstraZeneca, Spain.

References (9)

C. Escobar et al.
Selección de lo mejor del año 2017 en cardiología clínica. Novedades terapéuticas
Rev Esp Cardiol.
(2018)
T. Zelniker et al.
SGLT2 inhibitors for prevention of cardiovascular and renal outcomes in type 2 diabetes: meta-analysis of cardiovascular outcome trials
Lancet.
(2019)
B. Zinman et al.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
N Engl J Med.
(2015)
S. Verma et al.
SGLT2 inhibitors and mechanisms of cardiovascular benefit
Diabetologia.
(2018)

There are more references available in the full text version of this article.

Cited by (0)

View full text

Letter to the EditorStudies With Molecules Within the Same Class, but With Different Designs Yield Different Results. EMPA-REG, CANVAS and DECLAREEstudios con moléculas de la misma clase pero con diseños distintos ofrecen resultados diferentes: EMPA-REG, CANVAS y DECLARE

Section snippets

CONFLICTS OF INTEREST

Rev Esp Cardiol.

Lancet.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

N Engl J Med.

SGLT2 inhibitors and mechanisms of cardiovascular benefit

Diabetologia.

Letter to the Editor
Studies With Molecules Within the Same Class, but With Different Designs Yield Different Results. EMPA-REG, CANVAS and DECLAREEstudios con moléculas de la misma clase pero con diseños distintos ofrecen resultados diferentes: EMPA-REG, CANVAS y DECLARE